WO1998052565A1 - Substance dependence treatment using opiate antagonists and serotonin compounds - Google Patents
Substance dependence treatment using opiate antagonists and serotonin compounds Download PDFInfo
- Publication number
- WO1998052565A1 WO1998052565A1 PCT/US1998/010289 US9810289W WO9852565A1 WO 1998052565 A1 WO1998052565 A1 WO 1998052565A1 US 9810289 W US9810289 W US 9810289W WO 9852565 A1 WO9852565 A1 WO 9852565A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- person
- naltrexone
- treatment
- alcohol
- opioid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- This invention relates to the use of opioid antagonists such as naltrexone or nalmephene with serotonergic medication for substance dependence, to increase abstinence rates, reduce relapse once abstinence has been achieved, and to diminish side effects associated with the use of opiate antagonists.
- opioid antagonists such as naltrexone or nalmephene with serotonergic medication for substance dependence
- Dependence is an adaptive biological state induced by chronic drug exposure manifesting itself in various behavioral and physiological responses when drug exposure ceases. Withdrawal from alcohol following chronic use results in the emergence of an abstinence syndrome which reaches its peak intensity within the first few days. Cessation of alcohol consumption has been shown to result in a number of signs and symptoms of withdrawal such as increases in irritability, anxiety, restlessness, impatience, somatic complaints including nausea, insomnia, and tremulousness, and increases in heart rate and blood pressure as well as hallucinations and seizures, all of which are collectively called the alcohol with- drawal syndrome. Similarly, cessation of cocaine and opiate use also results in significant withdrawal symptomatology, while cessation of marijuana use results in a more subtle withdrawal syndrome.
- naltrexone alone has been found to increase abstinence and reduce relapse to heavy drinking in alcohol dependence, above that of placebo. Abstinence has been increased by naltrexone from approximately 25% to 50% over a 3 month period, and relapse to heavy drinking has been reduced from 50% to 25% over the same period. Following up at 6 months post cessation of naltrexone, there is a tendency for the naltrexone treated subjects to drink less than the non naltrexone group but not to the same extent immediately following treatment. However, not all alcohol dependent individuals benefit from naltrexone therapy and strategies to maximize treatment outcome are needed.
- naltrexone is approved for the treatment of opiate dependence, it is not considered an effective treatment for most people because compliance is so poor, presumably in part because naltrexone continues provoke subclinical signs and symptoms of opiate withdrawal even in the detoxified opiate addict. A new approach to opiate antagonist therapy that would be more tolerable would be of considerable value.
- an opioid antagonist such as nalmefene, naloxone, naltrexone, or a mixture of any of these, in combination with a serotonergic medication such as sertraline, fluoxetine, fluvoxamine, paroxetine, or odansetron.
- Naltrexone is used in one embodiment.
- This invention is based upon the finding that opioid antagonists in combination with serotonergic medications are useful in alcohol cessation treatments and in marijuana cessation, in cessation of cocaine, opiates and polysub- stance abuse.
- opioid antagonists alone are employed in treatments for alcoholism or other substance abuse disorders. Any opioid antagonist may be employed; naltrexone and/or related compounds are used in some preferred embodiments, but any other class of opioid antagonists may be used instead or in addition.
- Naltrexone, 17-(cyclopropyl- methyl)-4,5-epoxy-3, 14-dihydroxymorphinan-6-one is a congener of naloxone, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one, having opiate-blocking activity.
- Naltrexone related compounds include, but are not limited to, other structurally related opiate antagonists including naloxone, nalmefene (5 ⁇ -17-(cyclo- propylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol), and mixtures thereof. Naltrexone is used in one embodiment; nalmefene, in another.
- Administration of opioid antagonists or opioid antagonists in conjunction with other compounds can be local or systemic, or a combination of therapies.
- Systemic administration is preferred in some embodiments.
- Systemic administration can be via any method known in the art such as, for example, oral administration of lozenges, tablets, capsules, granules, or other edible compositions; intravenous, intramuscular, or intradermal administration, e.g. , by sterile injections, including depot versions; implants; parenteral administration of fluids, and the like.
- an antagonist or a compound mixture are typically topically applied to the skin or mucosa in association with a pharmaceutically acceptable carrier in which the antagonist is dispersed or solubilized.
- Carriers may be aqueous compositions, lotions, creams, ointments, soaps, and the like.
- the serotonergic medications described can be any one of a number of serotonergic medications including sertraline, fluoxetine, fluvoxamine, paroxetine, citalopram, zimeldine, viqualine, fenfluramine, d-fenfluramine, buspirone, gepirone, odansetron and/ or other related compounds.
- Administration of serotonergic medications or of serotonergic medications in conjunction with other compounds can be local or systemic, or a combination of therapies.
- Systemic administration is preferred in some embodiments. Systemic administration can be via any method known in the art and summarized above.
- a serotonergic medication or a compound mixture are typically topically applied to the skin or mucosa in association with a pharmaceutically acceptable carrier in which the antagonist is dispersed or solubilized such as that described for administration of the opioid antagonists described.
- Carriers may be aqueous compositions, lotions, creams, ointments, soaps, and the like.
- Naltrexone and/or related compounds are administered to a patient in amounts effective to reduce reinforcement from alcohol, cocaine, marijuana and opiates and polysubstance abuse during detoxification, and/or to prevent relapse after completion of detoxification.
- the amount of compound necessary to reduce reinforcement and prevent relapse during the therapeutic treatment of withdrawal, or to prevent relapse following detoxification is not fixed per se, and necessarily is dependent upon the severity and extent of substance dependence, the particular compound employed, and the method of administration.
- the compound is taken orally as a Revia(r)TM tablet.
- Typical doses vary from about 25 mg to about 100 mg, more narrowly from about 25 mg to about 150 mg daily, more narrowly from about 25 mg to about 100 mg. In one embodiment, smaller doses such as up to about 25 mg are employed. These compounds could be used to prevent relapse to use in alcohol, cocaine, opiate and marijuana abuse and polysubstance abuse.
- Serotonergic medications can also be administered in combination with opiate antagonists to treat symptoms of withdrawal, and to help treat relapse, and to increase abstinence.
- Typical doses vary from about 25 mg to 200 mg for sertraline, 10 mg to about 60 mg for fluoxetine, 25 mg to 200 mg for fluvoxamine, 10 mg to 50 mg for paroxetine, 10 mg to 60 mg for citalopram, 15 mg to 120 mg for fenfluramine or d-fenfluramine, and 5 mg to 60 mg of buspirone. These combinations could be used to prevent relapse to heavy use in alcohol, cocaine, opiate, and marijuana abuse and polysubstance abuse.
- the dependent individual is first placed on the serotonergic compound for a period of time, e.g., 1 to 7 days in one embodiment, and is then begun on naltrexone or the opiate antagonist.
- the dependent individual is placed on the initial dose of the opioid antagonist for a brief period.
- Naltrexone treatment may begin at either about 12.5 mg a day with increases up to about 50 mg after a week, or initially at levels of about 50 mg. Lower doses of about 12.5 or 25 mg may also be used throughout the entire treatment.
- a dose of the serotonergic medication could be added to the naltrexone regime and increased in dose to tolerance for a period from about 3 to 4 to about 12 months, the period of highest risk of relapse following complete detoxification.
- both compounds are begun simultaneously.
- the optimal sequence and dose for beginning therapy with naltrexone and the serotonergic compound might be made on the basis of clinical research experience.
- Alcoholism In alcoholism, opiate antagonists have been shown to reduce alcohol self-administration in monkeys (50% dose-dependent reduction over placebo; Altshuler, et al., Life Sciences, 1980, 26: 679-688) and rats bred for high and low alcohol preference (Froehlich, et ah, Alcohol and Alcoholism, 1987,
- naltrexone A significant benefit from the opiate antagonist naltrexone has been found in the treatment of alcohol dependent humans over 12 weeks in 2 large outpatient trials. Naltrexone in conjunction with psychotherapy produced a significant rise in complete abstinence from alcohol and a significant fall in relapse to heavy drinking (O'Malley, et al, 1995, 25: 681-689). Although the majority of researchers found that opiate antagonists reduce alcohol preference, not all studies have done so. For example, one researcher found an increase in alcohol consumption in hamsters given a single dose of naltrexone (Ross, et al., Proceedings of the Western Pharmacological Society, 1976, 19: 326-330).
- the serotonin system has also been implicated in the pathogenesis of alcoholism. Numerous animal studies have suggested a serotonin deficiency in alcohol consuming animals and a large number of human experiments have suggested a serotonergic deficiency in alcoholics relative to non alcoholics (Farren, Journal of Serotonin Research, 1995, 1: 9-26). In general, increased serotonin activity decreases alcohol intake and decreased serotonin function increases alcohol intake.
- the specific serotonin reuptake inhibitors including fluoxetine, fluvox- amine, citralopram and zimeldine have all been found to reduce alcohol consumption in alcohol preferring lines of rats (Murphy, et al., Alcohol, 1993, 2: 349-352).
- Sertraline a selective serotonin reuptake inhibitor, has been shown to significantly reduce the intake of alcohol in non-alcohol preferring male rats (Gill, et al., Alcohol, 1988, 5: 349-354).
- efforts to use serotonergic agents to treat alcohol dependence in humans has met with much less success than that shown in animals.
- Serotonergic reuptake inhibitors including zimeldine, citralopram, viqualine and fluoxetine have shown very small decreases (9 - 15%) in alcohol consumption in non alcohol dependent humans (Naranjo, et al., Clinical Pharma- cology and Therapeutics 1990, 47: 490-498).
- serotonin reuptake inhibitors such as fluoxetine, fluvoxamine, and dex-fenfluramine have shown benefit in reducing alcohol consumption (Kranzler, et al., Journal of Substance Abuse Treatment 1993, 10(3): 283-287; Gorelick and Pardes, Alcoholism: Clinical and Experimental Research, 1992, 16(2): 261-265; Romach, et al., Alcoholism: Clinical and Experimental Research, 1996, 20 (Suppl. 2), Abst #520).
- the serotonergic system has also been investigated with regards to cocaine abuse.
- Cocaine is a powerful serotonin reuptake inhibitor and chronic cocaine administration results in decreased 5-HT transmission, and this has been suggested as an explanation for the depressive symptoms of acute cocaine with- drawal (Cunningham, et al, Annals of the New York Academy of Sciences, 1992, 654: 117-127).
- Sertraline has been used, along with fluoxetine, in open label studies of cocaine abusers and has shown promise in decrease of cocaine craving, cocaine use and psychosocial function (Batki, et al, Journal of Clinical Psychopharmacology, 1993, 13: 243-250).
- Marijuana Cannabis (marijuana) is one of the most widely used drugs throughout the world and currently there are no successful pharmacotherapies to treat marijuana dependence.
- the psychoactive component of marijuana, tetrahy- drocannabinol (THC) produces a number of pharmacological effects in the CNS similar to those produced by opiates such as morphine including antinociception, hypothermia, respiratory depression, inhibition of locomotor activity and intestinal motility.
- opioid antagonists have been shown to block some of the pharmacological effects of THC.
- Preclinical studies have shown that, like alcohol, opiates (morphine) and other drugs of abuse, the reinforcing effects of THC are mediated by release of dopamine in the brain dopamine reward pathway.
- THC release of dopamine by THC can be blocked by the opioid antagonist naloxone, suggesting a role for the endogenous opioid peptides in modulating THC reinforcement similar to that documented above for alcohol dependence (Chen, et al, Psychopharmacology , 1990, 702: 156-162).
- THC also suppresses precipitated abstinence in morphine dependent rats and has also been shown to modulate brain opioid receptors (mu and delta) at pharmacologically relevant concentration.
- results described in the examples below show that a combination of opioid antagonist naltrexone and serotonergic uptake inhibitor sertraline are superior as an alcohol cessation treatment than naltrexone alone. Importantly, these results were obtained in a sample of nondepressed alcoholics. In addition, the results also describe a reduction in side effects of medication in the naltrexone and sertraline combination group. Results described in another example show that naltrexone and the serotonergic uptake inhibitor sertraline led to cessation of marijuana use in two patients.
- the invention has very important implications for successful treatment of alcohol withdrawal and for successful treatment of long term alcohol dependence.
- an opioid antagonist such as naltrexone
- Many individuals do not maintain complete abstinence and then relapse to heavy drinking.
- Naltrexone and a serotonergic medication together should enhance compliance and be more effective in encouraging abstinence and preventing relapse to heavy drinking.
- the invention is useful for developing appropriate strategies for using opioid antagonists in combination with other agents in the treatment of alcoholism.
- opioid antagonists with serotonin agents are useful with other substance abuse disorders involving alterations of the endogenous opioid system and the serotonergic system, or any other disorder, including non substance abuse related disorder, that has these abnormalities.
- the subjects in both groups were matched according to gender, family history of alcoholism, age, and the number of drinking days in the previous 90, and by the average drinks per drinking occasion.
- the naltrexone/sertraline group showed greater improvement than the naltrexone alone group. Only 44% of the naltrexone alone group remained abstinent for the duration of the trial, compared with 67% of the naltrexone/sertraline group; 56% of the naltrexone alone group did not relapse to heavy drinking, compared to 78% of the naltrexone/sertraline group; and the number of drinking occasions was higher for the naltrexone group (7.2 vs. 1.9).
- the invention was made with partial government support under NIH grant numbers K02-AA-00107 and K12-OA-00167. The government has certain rights in the invention.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP55056398A JP2002508753A (en) | 1997-05-20 | 1998-05-19 | Drug dependent treatment using opiate antagonists and serotonin compounds |
EP98923558A EP1011671A1 (en) | 1997-05-20 | 1998-05-19 | Substance dependence treatment using opiate antagonists and serotonin compounds |
CA002290788A CA2290788A1 (en) | 1997-05-20 | 1998-05-19 | Substance dependence treatment using opiate antagonists and serotonin compounds |
AU75824/98A AU7582498A (en) | 1997-05-20 | 1998-05-19 | Substance dependence treatment using opiate antagonists and serotonin compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4616297P | 1997-05-20 | 1997-05-20 | |
US60/046,162 | 1997-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998052565A1 true WO1998052565A1 (en) | 1998-11-26 |
Family
ID=21941947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/010289 WO1998052565A1 (en) | 1997-05-20 | 1998-05-19 | Substance dependence treatment using opiate antagonists and serotonin compounds |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1011671A1 (en) |
JP (1) | JP2002508753A (en) |
AU (1) | AU7582498A (en) |
CA (1) | CA2290788A1 (en) |
WO (1) | WO1998052565A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001068080A2 (en) * | 2000-03-15 | 2001-09-20 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
US6454789B1 (en) | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
JP2002541202A (en) * | 1999-04-09 | 2002-12-03 | サザン・リサーチ・インスティテュート | Injectable naltrexone microsphere composition and its use for reducing heroin and alcohol intake |
WO2004078177A1 (en) * | 2003-03-07 | 2004-09-16 | Toray Industries Inc. | Remedy for drug/substance dependence |
US9278094B2 (en) | 2013-01-30 | 2016-03-08 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
CN106456634A (en) * | 2014-04-22 | 2017-02-22 | 大塚制药株式会社 | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
-
1998
- 1998-05-19 JP JP55056398A patent/JP2002508753A/en active Pending
- 1998-05-19 AU AU75824/98A patent/AU7582498A/en not_active Abandoned
- 1998-05-19 EP EP98923558A patent/EP1011671A1/en not_active Withdrawn
- 1998-05-19 WO PCT/US1998/010289 patent/WO1998052565A1/en not_active Application Discontinuation
- 1998-05-19 CA CA002290788A patent/CA2290788A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6454789B1 (en) | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
JP2002541202A (en) * | 1999-04-09 | 2002-12-03 | サザン・リサーチ・インスティテュート | Injectable naltrexone microsphere composition and its use for reducing heroin and alcohol intake |
JP2010031036A (en) * | 1999-04-09 | 2010-02-12 | Brookwood Pharmaceuticals Inc | Injectable naltrexone microsphere composition, and use thereof for reducing consumption of heroin and alcohol |
WO2001068080A2 (en) * | 2000-03-15 | 2001-09-20 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
WO2001068080A3 (en) * | 2000-03-15 | 2002-07-04 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
US6713488B2 (en) | 2000-03-15 | 2004-03-30 | Sadee Wolfgang | Neutral antagonists and use thereof in treating drug abuse |
WO2004078177A1 (en) * | 2003-03-07 | 2004-09-16 | Toray Industries Inc. | Remedy for drug/substance dependence |
US9278094B2 (en) | 2013-01-30 | 2016-03-08 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
CN106456634A (en) * | 2014-04-22 | 2017-02-22 | 大塚制药株式会社 | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
US11642341B2 (en) | 2014-04-22 | 2023-05-09 | Otsuka Pharmaceutical Co., Ltd. | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
Also Published As
Publication number | Publication date |
---|---|
AU7582498A (en) | 1998-12-11 |
JP2002508753A (en) | 2002-03-19 |
CA2290788A1 (en) | 1998-11-26 |
EP1011671A1 (en) | 2000-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0687175B1 (en) | Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures | |
RU2492858C2 (en) | Compositions and methods of preventing and treating addictions | |
Ye et al. | Ondansetron: a selective 5‐HT3 receptor antagonist and its applications in CNS‐related disorders | |
Mello et al. | Buprenorphine suppresses cocaine self-administration by rhesus monkeys | |
US5075341A (en) | Treatment for cocaine abuse | |
Kleber | Pharmacologic treatments for heroin and cocaine dependence | |
US6004970A (en) | Smoking cessation treatments using naltrexone and related compounds | |
MX2007012355A (en) | Methods for the treatment of substance abuse and dependence. | |
WO1995015757A1 (en) | Method of attenuating nerve injury induced pain | |
Soyka et al. | Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective | |
KR20020081271A (en) | Methods for the treatment of substance abuse | |
WO1998052565A1 (en) | Substance dependence treatment using opiate antagonists and serotonin compounds | |
Welch et al. | Opiate antagonists for the treatment of schizophrenia | |
Sim | Methadone | |
AU672772B2 (en) | Alleviating or prevention of migraine headache onset with mast cell degranulation blocking agents | |
EP1815853B1 (en) | Therapeutic agent ((-)-bpap) for drug dependence | |
WO2003088918A2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING α3β4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE | |
Singh et al. | Opioid antagonists. I: Pharmacology and rationale for use in treating self-injury | |
McCance-Katz et al. | Psychopharmacological treatments | |
Kampman | Biologic Treatments for Drug and Alcohol Dependence. | |
Stahl | Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough | |
Kleber | Detoxification from Methadone Maintenance: Current and Innovative Approaches | |
Giannini et al. | P's and blues: potentiation of propoxyphene withdrawal by a variety of antihistamines | |
Nguyen et al. | Pharmacotherapies for treating opioid use disorder | |
Ey | Naltrexone hydrochloride use in the treatment of alcoholism. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2290788 Country of ref document: CA Ref country code: CA Ref document number: 2290788 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09424171 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998923558 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 75824/98 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998550563 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998923558 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998923558 Country of ref document: EP |